Gilead disputes need for march-in rights to remdesivir to increase access, lower price

COVID-19 has spurred the latest demand for the federal government to exercise a power, yet unused, to lower drug prices by terminating a manufacturer’s exclusive license.

In a letter Tuesday, 34 U.S. attorneys general urged FDA and NIH to license remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) to a third party to increase production of the antiviral and lower its $520-per-vial price tag. ...